These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34970991)

  • 21. CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia.
    van der Ende EL; Morenas-Rodriguez E; McMillan C; Grossman M; Irwin D; Sanchez-Valle R; Graff C; Vandenberghe R; Pijnenburg YAL; Laforce R; Ber IL; Lleo A; Haass C; Suarez-Calvet M; van Swieten JC; Seelaar H
    Neurobiol Aging; 2021 Jul; 103():158.e1-158.e5. PubMed ID: 33896652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble TREM2 is a potential biomarker for the severity of primary angiitis of the CNS.
    Guo T; Ma J; Sun J; Xu W; Cong H; Wei Y; Ma Y; Dong Q; Kou Y; Yin L; Zhang X; Chang H; Wang H
    Front Immunol; 2022; 13():963373. PubMed ID: 36636326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
    Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
    Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The
    Deming Y; Filipello F; Cignarella F; Cantoni C; Hsu S; Mikesell R; Li Z; Del-Aguila JL; Dube U; Farias FG; Bradley J; Budde J; Ibanez L; Fernandez MV; Blennow K; Zetterberg H; Heslegrave A; Johansson PM; Svensson J; Nellgård B; Lleo A; Alcolea D; Clarimon J; Rami L; Molinuevo JL; Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Ewers M; Harari O; Haass C; Brett TJ; Benitez BA; Karch CM; Piccio L; Cruchaga C
    Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification.
    Knapskog AB; Henjum K; Idland AV; Eldholm RS; Persson K; Saltvedt I; Watne LO; Engedal K; Nilsson LNG
    Sci Rep; 2020 Sep; 10(1):15886. PubMed ID: 32985583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early increment of soluble triggering receptor expressed on myeloid cells 2 in plasma might be a predictor of poor outcome after ischemic stroke.
    Kwon HS; Lee EH; Park HH; Jin JH; Choi H; Lee KY; Lee YJ; Lee JH; de Oliveira FMS; Kim HY; Seo Kim Y; Kim BJ; Heo SH; Chang DI; Kamali-Moghaddam M; Koh SH
    J Clin Neurosci; 2020 Mar; 73():215-218. PubMed ID: 32067825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.
    Franzmeier N; Suárez-Calvet M; Frontzkowski L; Moore A; Hohman TJ; Morenas-Rodriguez E; Nuscher B; Shaw L; Trojanowski JQ; Dichgans M; Kleinberger G; Haass C; Ewers M;
    Mol Neurodegener; 2020 Oct; 15(1):57. PubMed ID: 33032659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.
    Ashton NJ; Suárez-Calvet M; Heslegrave A; Hye A; Razquin C; Pastor P; Sanchez-Valle R; Molinuevo JL; Visser PJ; Blennow K; Hodges AK; Zetterberg H
    Alzheimers Res Ther; 2019 Nov; 11(1):94. PubMed ID: 31779670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild-type sTREM2 blocks Aβ aggregation and neurotoxicity, but the Alzheimer's R47H mutant increases Aβ aggregation.
    Vilalta A; Zhou Y; Sevalle J; Griffin JK; Satoh K; Allendorf DH; De S; Puigdellívol M; Bruzas A; Burguillos MA; Dodd RB; Chen F; Zhang Y; Flagmeier P; Needham LM; Enomoto M; Qamar S; Henderson J; Walter J; Fraser PE; Klenerman D; Lee SF; St George-Hyslop P; Brown GC
    J Biol Chem; 2021; 296():100631. PubMed ID: 33823153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
    Rauchmann BS; Schneider-Axmann T; Alexopoulos P; Perneczky R;
    Neurobiol Aging; 2019 Feb; 74():182-190. PubMed ID: 30458365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble TREM2 induces inflammatory responses and enhances microglial survival.
    Zhong L; Chen XF; Wang T; Wang Z; Liao C; Wang Z; Huang R; Wang D; Li X; Wu L; Jia L; Zheng H; Painter M; Atagi Y; Liu CC; Zhang YW; Fryer JD; Xu H; Bu G
    J Exp Med; 2017 Mar; 214(3):597-607. PubMed ID: 28209725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
    Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
    Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.
    Zhong L; Xu Y; Zhuo R; Wang T; Wang K; Huang R; Wang D; Gao Y; Zhu Y; Sheng X; Chen K; Wang N; Zhu L; Can D; Marten Y; Shinohara M; Liu CC; Du D; Sun H; Wen L; Xu H; Bu G; Chen XF
    Nat Commun; 2019 Mar; 10(1):1365. PubMed ID: 30911003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels.
    Hou XH; Bi YL; Tan MS; Xu W; Li JQ; Shen XN; Dou KX; Tan CC; Tan L; ; Yu JT
    Neurobiol Aging; 2019 Dec; 84():241.e13-241.e20. PubMed ID: 31204042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection.
    Gisslén M; Heslegrave A; Veleva E; Yilmaz A; Andersson LM; Hagberg L; Spudich S; Fuchs D; Price RW; Zetterberg H
    Neurol Neuroimmunol Neuroinflamm; 2019 Jan; 6(1):e512. PubMed ID: 30568991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TREM2 ectodomain and its soluble form in Alzheimer's disease.
    Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
    J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
    Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
    EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants.
    Schindler SE; Cruchaga C; Joseph A; McCue L; Farias FHG; Wilkins CH; Deming Y; Henson RL; Mikesell RJ; Piccio L; Llibre-Guerra JJ; Moulder KL; Fagan AM; Ances BM; Benzinger TLS; Xiong C; Holtzman DM; Morris JC
    Neurol Genet; 2021 Apr; 7(2):e571. PubMed ID: 33884297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long sleep duration in elders without dementia increases risk of dementia mortality (NEDICES).
    Benito-León J; Louis ED; Villarejo-Galende A; Romero JP; Bermejo-Pareja F
    Neurology; 2014 Oct; 83(17):1530-7. PubMed ID: 25253755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.